

## HR 4200

To amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.

**Congress:** 110 (2007–2009, Ended)

**Chamber:** House

**Policy Area:** Taxation

**Introduced:** Nov 15, 2007

**Current Status:** Referred to the House Committee on Ways and Means.

**Latest Action:** Referred to the House Committee on Ways and Means. (Nov 15, 2007)

**Official Text:** <https://www.congress.gov/bill/110th-congress/house-bill/4200>

### Sponsor

**Name:** Rep. Towns, Edolphus [D-NY-10]

**Party:** Democratic • **State:** NY • **Chamber:** House

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Davis, Danny K. [D-IL-7]	D · IL		Nov 15, 2007
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Nov 15, 2007
Rep. Wynn, Albert Russell [D-MD-4]	D · MD		Nov 15, 2007
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Dec 4, 2007

### Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Nov 15, 2007

### Subjects & Policy Tags

**Policy Area:**

Taxation

### Related Bills

Bill	Relationship	Last Action
110 S 2351	Identical bill	<b>Nov 14, 2007:</b> Read twice and referred to the Committee on Finance.

### Summary (as of Nov 15, 2007)

Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.

## Actions Timeline

---

- **Nov 15, 2007:** Introduced in House
- **Nov 15, 2007:** Referred to the House Committee on Ways and Means.